sFlt-1/PLGF比值在子痫前期中的应用进展  

Application progress of sFlt-1/PLGF ratio in preeclampsia

作　　者：山蕾 周涛[1] 邱娟娟 倪晴 柏婷 彭兰[2] Shan Lei;Zhou Tao;Qiu Juanjuan;Ni Qing;Bo Ting;Peng Lan(Department of Obstetrics,Quzhou Hospital Affiliated to Wenzhou Medical University,Zhejiang,Quzhou 324000,China;Department of Obstetrics,the Affiliated Suzhou Hospital of Nanjing Medical University,Jiangsu,Suzhou 215000,China)

机构地区：[1]温州医科大学附属衢州医院产科,浙江衢州324000 [2]南京医科大学附属苏州医院产科,江苏苏州215000

出　　处：《发育医学电子杂志》2025年第2期154-160,共7页Journal of Developmental Medicine (Electronic Version)

基　　金：南京医科大学姑苏学院专病队列项目(GSKY20220410);苏州市医疗卫生科技创新(指令性)项目(SKY2022056)。

摘　　要：子痫前期是导致母婴不良结局甚至死亡的最常见原因之一。可溶性fms样酪氨酸激酶-1(soluble fms-like tyrosine kinase-1,sFlt-1)与胎盘生长因子(placental growth factor,PLGF)的比值直接反映了胎盘合体滋养细胞的失衡状态,有望成为子痫前期预测、辅助诊断和预后的关键生物标志物。本文概述了sFlt-1/PLGF比值在子痫前期发病过程和疾病进展中的病理生理作用,并综述了sFlt-1/PLGF比值在子痫前期诊断、预测、治疗等方面的临床研究进展。Preeclampsia is one of the most common causes of adverse maternal and neonatal outcomes,even death.The ratio of soluble fms-like tyrosine kinase-1(sFlt-1)and placental growth factor(PLGF)as a direct indicator of the dysregulation within placental syncytiotrophoblast cells.This ratio is poised to emerge as a pivotal biomarker for the prediction,auxiliary diagnosis,and prognosis of preeclampsia.This article delineates the pathophysiological role of the sFlt-1/PLGF ratio in the etiology and progression of preeclampsia.Furthermore,it offers a comprehensive summary of the clinical research advancements concerning the application of the sFlt-1/PLGF ratio in diagnosing,predicting,and treatment of preeclampsia.

关 键 词：子痫前期 妊娠期高血压疾病 血管生成因子 胎盘生长因子 血管生成 

分 类 号：R71[医药卫生—妇产科学]